Open Access
Open access
JAMA network open, volume 5, issue 8, pages e2228997

Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

Timothy S. Anderson 1, 2
Aileen A. O’Donoghue 2
Oren Mechanic 3, 4
Tenzin Dechen 2
1
 
Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
2
 
Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, Massachusetts
4
 
Department of Emergency Medicine, Mount Sinai Medical Center, Miami Beach, Florida
5
 
Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Publication typeJournal Article
Publication date2022-08-29
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor13.8
ISSN25743805
General Medicine
Abstract
This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.

Top-30

Citations by journals

1
2
3
Viruses
3 publications, 18.75%
Life
2 publications, 12.5%
Drug Resistance Updates
2 publications, 12.5%
Journal of Clinical Investigation
1 publication, 6.25%
Molecular Biomedicine
1 publication, 6.25%
Annals of Internal Medicine
1 publication, 6.25%
Clinical Microbiology Reviews
1 publication, 6.25%
Clinical Microbiology and Infection
1 publication, 6.25%
Expert Opinion on Biological Therapy
1 publication, 6.25%
Russian Chemical Reviews
1 publication, 6.25%
Clinical Infectious Diseases
1 publication, 6.25%
1
2
3

Citations by publishers

1
2
3
4
5
Multidisciplinary Digital Publishing Institute (MDPI)
5 publications, 31.25%
Elsevier
3 publications, 18.75%
American Society for Clinical Investigation
1 publication, 6.25%
Springer Nature
1 publication, 6.25%
American College of Physicians
1 publication, 6.25%
Cold Spring Harbor Laboratory
1 publication, 6.25%
American Society for Microbiology
1 publication, 6.25%
Taylor & Francis
1 publication, 6.25%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 6.25%
Oxford University Press
1 publication, 6.25%
1
2
3
4
5
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Anderson T. S. et al. Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization // JAMA network open. 2022. Vol. 5. No. 8. p. e2228997.
GOST all authors (up to 50) Copy
Anderson T. S., O’Donoghue A. A., Mechanic O., Dechen T., Stevens J. Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization // JAMA network open. 2022. Vol. 5. No. 8. p. e2228997.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1001/jamanetworkopen.2022.28997
UR - https://doi.org/10.1001/jamanetworkopen.2022.28997
TI - Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization
T2 - JAMA network open
AU - Anderson, Timothy S.
AU - O’Donoghue, Aileen A.
AU - Mechanic, Oren
AU - Dechen, Tenzin
AU - Stevens, Jennifer
PY - 2022
DA - 2022/08/29 00:00:00
PB - American Medical Association (AMA)
SP - e2228997
IS - 8
VL - 5
SN - 2574-3805
ER -
BibTex |
Cite this
BibTex Copy
@article{2022_Anderson,
author = {Timothy S. Anderson and Aileen A. O’Donoghue and Oren Mechanic and Tenzin Dechen and Jennifer Stevens},
title = {Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization},
journal = {JAMA network open},
year = {2022},
volume = {5},
publisher = {American Medical Association (AMA)},
month = {aug},
url = {https://doi.org/10.1001/jamanetworkopen.2022.28997},
number = {8},
pages = {e2228997},
doi = {10.1001/jamanetworkopen.2022.28997}
}
MLA
Cite this
MLA Copy
Anderson, Timothy S., et al. “Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization.” JAMA network open, vol. 5, no. 8, Aug. 2022, p. e2228997. https://doi.org/10.1001/jamanetworkopen.2022.28997.
Found error?